ACETAMINOPHEN
| Brand name | OFIRMEV |
|---|---|
| Active ingredient | ACETAMINOPHEN |
| Strength | 1GM/100ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | November 2010 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 9399012*PED | March 2032 | — |
| 9399012 | September 2031 | use U-2261 |
| 10383834*PED | May 2029 | — |
| 9610265*PED | May 2029 | — |
| 9987238*PED | May 2029 | — |
| 9987238 | November 2028 | use U-2261 |
| 9610265 | November 2028 | use U-2263 |
| 10383834 | November 2028 | use U-2621 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.